Evidence map›Paper›PMID 28178884›Full record

ArticleStem cells and development2017

Improved Post-Thaw Function and Epigenetic Changes in Mesenchymal Stromal Cells Cryopreserved Using Multicomponent Osmolyte Solutions.

Kathryn Pollock, Rebekah M Samsonraj, Amel Dudakovic, Roman Thaler, Aron Stumbras, David H McKenna, Peter I Dosa, Andre J van Wijnen, Allison Hubel

Abstract read
In one paragraph

Article in Stem cells and development, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 54 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. The Evolving Landscape of Potency Assays.Advances in experimental medicine and biology · 2023
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Kathryn Pollock1 Department of Biomedical Engineering, University of Minnesota , Minneapolis, Minnesota.
Rebekah M Samsonraj2 Department of Orthopedic Surgery, Mayo Clinic , Rochester, Minnesota.
Amel Dudakovic2 Department of Orthopedic Surgery, Mayo Clinic , Rochester, Minnesota.
Roman Thaler2 Department of Orthopedic Surgery, Mayo Clinic , Rochester, Minnesota.
Aron Stumbras3 Stem Cell Institute, University of Minnesota , Minneapolis, Minnesota.
David H McKenna4 Department of Laboratory Medicine and Pathology, University of Minnesota , Minneapolis, Minnesota.
Peter I Dosa5 Institute for Therapeutics Discovery and Development, University of Minnesota , Minneapolis, Minnesota.
Andre J van Wijnen2 Department of Orthopedic Surgery, Mayo Clinic , Rochester, Minnesota.
Allison Hubel6 Department of Mechanical Engineering, University of Minnesota , Minneapolis, Minnesota.
University of Minnesota · USMayo Clinic · US

Funding

Women's CancerP30CA077598 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Douglas Yee · 1998 to 2026
$100.4M
Molecular Control of Bone FormationR01AR049069 · NIAMS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI WESTENDORF, JENNIFER J · 2003 to 2021
$5.8M
Integrated training in development and clinical practice of cell-based therapiesR25HL128372 · NHLBI · UNIVERSITY OF MINNESOTA · PI HUBEL, ALLISON, MCKENNA, DAVID HURLEY · 2015 to 2019
$553k
Technology platform for development of multi-component preservation solutionR21EB016247 · NIBIB · UNIVERSITY OF MINNESOTA · PI HUBEL, ALLISON · 2013 to 2014
$387k
Epigenetic control of osteoblast differentiationF32AR066508 · NIAMS · MAYO CLINIC ROCHESTER · PI DUDAKOVIC, AMEL · 2015 to 2017
$185k
NCI NIH HHS P30 CA077598NHLBI NIH HHS R25 HL128372NIAMS NIH HHS F32 AR066508NIAMS NIH HHS R01 AR049069NIBIB NIH HHS R21 EB016247
6 · The paper itself

Abstract

Current methods for freezing mesenchymal stromal cells (MSCs) result in poor post-thaw function, which limits the clinical utility of these cells. This investigation develops a novel approach to preserve MSCs using combinations of sugars, sugar alcohols, and small-molecule additives. MSCs frozen using these solutions exhibit improved post-thaw attachment and a more normal alignment of the actin cytoskeleton compared to cells exposed to dimethylsulfoxide (DMSO). Osteogenic and chondrogenic differentiation assays show that cells retain their mesenchymal lineage properties. Genomic analysis indicates that the different freezing media evaluated have different effects on the levels of DNA hydroxymethylation, which are a principal epigenetic mark and a key step in the demethylation of CpG doublets. RNA sequencing and quantitative real time-polymerase chain reaction validation demonstrate that transcripts for distinct classes of cytoprotective genes, as well as genes related to extracellular matrix structure and growth factor/receptor signaling are upregulated in experimental freezing solutions compared to DMSO. For example, the osmotic regulator galanin, the antiapoptotic marker B cell lymphoma 2, as well as the cell surface adhesion molecules CD106 (vascular cell adhesion molecule 1) and CD54 (intracellular adhesion molecule 1) are all elevated in DMSO-free solutions. These studies validate the concept that DMSO-free solutions improve post-thaw biological functions and are viable alternatives for freezing MSCs. These novel solutions promote expression of cytoprotective genes, modulate the CpG epigenome, and retain the differentiation ability of MSCs, suggesting that osmolyte-based freezing solutions may provide a new paradigm for therapeutic cell preservation.

Indexed as

CryopreservationActin CytoskeletonBiomarkersCell DifferentiationCell LineCell ProliferationCell SurvivalCellular SenescenceCryoprotective AgentsDimethyl SulfoxideDNA MethylationEpigenesis, GeneticFreezingGene Expression RegulationHumansMesenchymal Stem CellsBiomarkersCryoprotective AgentsDimethyl SulfoxideSolutionsamino acidscryopreservationepigeneticmesenchymal stromal cellssaccharides

Identifiers

PMID28178884
PMCPMC5466057
OpenAlexW2610336196

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.